Galera Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Galera Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($1.39M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($1.08M) | Aug 13, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($1.08M) | Nov 13, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($1.59M) | Nov 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($1.59M) | May 15, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($1.59M) | Aug 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($5.58M) | Nov 13, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($4.06M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($4.06M) | Aug 13, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($4.38M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($4.38M) | May 15, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($4.38M) | Nov 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($15.07M) | Dec 13, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($20.71M) | Dec 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($20.71M) | Aug 14, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($17.71M) | Aug 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($17.71M) | May 13, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($17.71M) | Dec 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($16.03M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($14.56M) | Aug 14, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($1.44M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($1.14M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($1.96M) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($5.91M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($4.21M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($4.58M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($13.40M) | Dec 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($16.81M) | Aug 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($13.88M) | May 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($12.96M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($11.93M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($13.15M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($20.30M) | Nov 9, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($21.09M) | Aug 9, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($17.48M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($16.08M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($17.71M) | Aug 10, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($17.82M) | May 11, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($12.86M) | Nov 10, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($11.27M) | Aug 10, 2020 |